Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 29/100

Termination Rate

9.7%

3 terminated out of 31 trials

Success Rate

85.0%

-1.5% vs benchmark

Late-Stage Pipeline

42%

13 trials in Phase 3/4

Results Transparency

41%

7 of 17 completed with results

Key Signals

7 with results85% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (1)
P 1 (2)
P 2 (3)
P 3 (9)
P 4 (4)

Trial Status

Completed17
Recruiting7
Terminated3
Unknown2
Not Yet Recruiting1
Withdrawn1

Trial Success Rate

85.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (31)

Showing 20 of 20 trials
NCT05858606Not ApplicableRecruitingPrimary

Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients

NCT07221851Phase 3Recruiting

Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

NCT06382155Phase 2RecruitingPrimary

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

NCT06927310Phase 3RecruitingPrimary

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

NCT07450053Phase 1Not Yet RecruitingPrimary

A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)

NCT05894876TerminatedPrimary

A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature

NCT06309979RecruitingPrimary

A Study to Assess Growth in Children With Idiopathic Short Stature

NCT04020913Completed

Skeletal Muscle Effects of GH in Boys

NCT05838885Phase 2CompletedPrimary

A Trial of YPEG-rhGH in Children With Short Stature

NCT00840944Phase 4UnknownPrimary

A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height

NCT04798690Recruiting

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

NCT02973061Unknown

The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents

NCT01604395Recruiting

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

NCT00488124Phase 2CompletedPrimary

Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin

NCT01438801Phase 4WithdrawnPrimary

Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)

NCT00710307CompletedPrimary

Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)

NCT01248416Phase 3CompletedPrimary

Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature

NCT01246219Phase 4CompletedPrimary

Short Stature Related Distress

NCT01786902Phase 3CompletedPrimary

Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature

NCT01778023Phase 3Completed

Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature

Scroll to load more

Research Network

Activity Timeline